UBS Group
CPRX icon

UBS Group’s Catalyst Pharmaceutical CPRX Stock Holding History

UBS Group’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-500
Closed -$2K – 8526
2015
Q1 		$2K Buy
500
+200
+67% +$721 ﹤0.01% 8435
2014
Q4 		$1K Buy
+300
New +$823 ﹤0.01% 9527

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

UBS Group's CPRX Position: Q1 2026 in Review

UBS Group increased its Catalyst Pharmaceutical (CPRX) stake by 52% in Q1 2026, buying an estimated $8.03M and bringing the position to 986,090 shares worth $24.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2375.

UBS Group first reported a position in CPRX in Q2 2015 and has held it in 35 quarters since. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • UBS Group held 986,090 shares of Catalyst Pharmaceutical worth $24.4M as of Q1 2026.
  • UBS Group bought 337,103 Catalyst Pharmaceutical shares in Q1 2026, an estimated $8.03M.
  • Catalyst Pharmaceutical made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #2375 holding.
  • UBS Group first reported a position in Catalyst Pharmaceutical in Q2 2015 and has held it in 35 quarters since.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.